2025 年第 6 期 第 20 卷

羚羊清肺丸联合哌拉西林钠他唑巴坦钠治疗重症肺炎的临床研究

Clinical study of Lingyang Qingfei pill combined with piperacillin sodium and tazobactam sodium in the treatment of severe pneumonia

作者：张云李昕玲李丽

英文作者：Zhang Yun Li Xinling Li Li

单位：中国人民解放军北部战区总医院呼吸与危重症医学科，沈阳110000

英文单位：Department of Respiratory and Critical Care Medicine General Hospital of Northern Theater Command of Chinese People′s Liberation Army Shenyang 110000 China

关键词：重症肺炎；羚羊清肺丸；哌拉西林钠他唑巴坦钠

英文关键词：Severepneumonia;LingyangQingfeipill;Piperacillinsodiumandtazobactamsodium

• 摘要：

• 目的 探讨羚羊清肺丸联合哌拉西林钠他唑巴坦钠治疗重症肺炎患者的效果。方法 选取2020年10月至2023年10月中国人民解放军北部战区总医院收治的125例重症肺炎患者作为研究对象。按照随机数字表法分为对照组（62例）和观察组（63例）。所有患者均给予常规治疗。对照组给予哌拉西林钠他唑巴坦钠治疗，观察组在对照组基础上给予羚羊清肺丸治疗，2组均连续治疗14 d。比较2组患者的临床疗效、症状消失时间、肺功能指标、炎性因子指标、安全性。结果 观察组总有效率明显高于对照组［96.8%（61/63）比74.2%（46/62）］（χ2=12.985，P＜0.001）。治疗后观察组的退热时间、气促消失时间、咳嗽消失时间、湿啰音消失时间均短于对照组，差异均有统计学意义（均P<0.05）。治疗后，2组用力肺活量、第1秒用力呼气容积及部分呼气流量-容积均高于治疗前，且观察组均高于对照组，差异均有统计学意义（均P<0.05）。治疗后，2组血清C反应蛋白、白细胞介素6及降钙素原水平均低于治疗前，且观察组均低于对照组，差异均有统计学意义（均P<0.05）。观察组和对照组不良反应发生率比较差异无统计学意义［7.9%（5/63）比4.8%（3/62）］（χ2=0.501，P=0.479）。结论 羚羊清肺丸联合哌拉西林钠他唑巴坦钠对重症肺炎有较好疗效，可缓解临床症状，改善肺功能，降低炎性因子水平，且安全性较好。

• Objective To investigate the effect of Lingyang Qingfei pill combined with piperacillin sodium and tazobactam sodium in the treatment of patients with severe pneumonia. Methods A total of 125 patients with severe pneumonia admitted to the General Hospital of the Northern Theater Command  of Chinese People′s Liberation Army from October 2020 to October 2023 were selected as the research objects. According to the random number table method, they were divided into the control group (62 cases) and the observation group (63 cases). All patients were given conventional treatment. The control group was treated with piperacillin sodium and tazobactam sodium, and the observation group was treated with Lingyang Qingfei pill on the basis of the control group. Both groups were treated for 14 days. The clinical efficacy, symptom disappearance time, pulmonary function index, inflammatory factor index and safety of the two groups were compared. Results The total effective rate of the observation group was significantly higher than that of the control group ［96.8%(61/63) vs 74.2%(46/62)］(χ2=12.985, P＜0.001). After treatment, the antipyretic time, shortness of breath disappearance time, cough disappearance time and wet rales disappearance time of the observation group were shorter than those of the control group (all P＜0.05). After treatment, the forced vital capacity, forced expiratory volume in the first second and partial expiratory flow-volume of the two groups were higher than those before treatment, and those of the observation group were higher than those of the control group (all P＜0.05). After treatment, the levels of serum C-reactive protein, interleukin-6 and procalcitonin in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (all P＜0.05). There was no significant difference in the incidence of adverse reactions between the observation group and the control group ［7.9%(5/63) vs 4.8%(3/62)］(χ2=0.501, P=0.479). Conclusion Lingyang Qingfei pill combined with piperacillin sodium and tazobactam sodium has a good effect on severe pneumonia, which can relieve clinical symptoms, improve lung function, reduce inflammatory factors, and has good safety.